Literature for bortezomib (T01.010, T01.011, T01.012 inhibitor)

Summary Structure Literature

(Topics flags: S Structure, T Target, K Knockout, P Specificity, V Review, M Mutation, I Inhibitor, L Localization. To select only the references relevant to a single topic, click the link above. See explanation.)

2020

Vora,P.A., Patel,R. and Dharamsi,A. Bortezomib - first therapeutic proteasome inhibitor for cancer therapy: a review of patent literature Recent Pat Anticancer Drug Discov (2020) 15, 113-131. PubMed Europe PubMed DOI V I

2019

Besse,A., Besse,L., Kraus,M., Mendez-Lopez,M., Bader,J., Xin,B.T., de Bruin,G., Maurits,E., Overkleeft,H.S. and Driessen,C. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors Cell Chem Biol (2019) 26, 340-351. PubMed Europe PubMed DOI I
Dang,Q., Chen,L., Xu,M., You,X., Zhou,H., Zhang,Y. and Shi,W. The gamma-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis Cell Signal (2019) 59, 76-84. PubMed Europe PubMed DOI I
Felix,J., Weinhaupl,K., Chipot,C., Dehez,F., Hessel,A., Gauto,D.F., Morlot,C., Abian,O., Gutsche,I., Velazquez-Campoy,A., Schanda,P. and Fraga,H. Mechanism of the allosteric activation of the ClpP protease machinery by substrates and active-site inhibitors Sci Adv (2019) 5, eaaw3818-eaaw3818. PubMed Europe PubMed DOI PMC EPMC I
Kuroda,K. and Liu,H. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor Int J Oncol (2019) 54, 1357-1366. PubMed Europe PubMed DOI I
Lee,M.J., Bhattarai,D., Yoo,J., Miller,Z., Park,J.E., Lee,S., Lee,W., Driscoll,J.J. and Kim,K.B. Development of novel epoxyketone-based proteasome inhibitors as a strategy to overcome cancer resistance to carfilzomib and bortezomib J Med Chem (2019) 62, 4444-4455. PubMed Europe PubMed DOI I
Liu,S., Liu,H., Zhang,K., Li,X., Duan,Y., Wang,Z. and Wang,T. Proteasome inhibitor PS-341 effectively blocks infection by the Severe Fever with Thrombocytopenia Syndrome virus Virol Sin (2019) 34, 572-582. PubMed Europe PubMed DOI I

2018

Xu,Y., Yang,X., Chen,Y., Chen,H., Sun,H., Li,W., Xie,Q., Yu,L. and Shao,L. Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib Bioorg Med Chem Lett (2018) 28, 2148-2152. PubMed Europe PubMed DOI I

2017

Moreira,W., Santhanakrishnan,S., Ngan,G.J., Low,C.B., Sangthongpitag,K., Poulsen,A., Dymock,B.W. and Dick,T. Towards selective mycobacterial ClpP1P2 inhibitors with reduced activity against the human proteasome Antimicrob Agents Chemother (2017) 61, e02307-16-e02307-16. PubMed Europe PubMed DOI I
Moreira,W., Santhanakrishnan,S., Dymock,B.W. and Dick,T. Bortezomib warhead-switch confers dual activity against mycobacterial caseinolytic protease and proteasome and selectivity against human proteasome Front Microbiol (2017) 8, 746-746. PubMed Europe PubMed DOI PMC EPMC I
Weyburne,E.S., Wilkins,O.M., Sha,Z., Williams,D.A., Pletnev,A.A., de Bruin,G., Overkleeft,H.S., Goldberg,A.L., Cole,M.D. and Kisselev,A.F. Inhibition of the proteasome beta2 site sensitizes triple-negative breast cancer cells to beta5 inhibitors and suppresses Nrf1 activation Cell Chem Biol (2017) 24, 218-230. PubMed Europe PubMed DOI T I

2016

Csizmadia,V., Hales,P., Tsu,C., Ma,J., Chen,J., Shah,P., Fleming,P., Senn,J.J., Kadambi,V.J., Dick,L. and Wolenski,F.S. Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi Toxicol Res (2016) 5, 1619-1628. DOI I
de Bruin,G., Mock,E.D., Hoogendoorn,S., van den Nieuwendijk,A.M., Mazurek,J., van der Marel,G.A., Florea,B.I. and Overkleeft,H.S. Enantioselective synthesis of adamantylalanine and carboranylalanine and their incorporation into the proteasome inhibitor bortezomib Chem Commun (Camb) (2016) 52, 4064-4067. PubMed Europe PubMed DOI I
Tew,K.D. Commentary on "Proteasome inhibitors: a novel class of potent and effective antitumor agents" Cancer Res (2016) 76, 4916-4917. PubMed Europe PubMed DOI I
Toscani,D., Palumbo,C., Dalla Palma,B., Ferretti,M., Bolzoni,M., Marchica,V., Sena,P., Martella,E., Mancini,C., Ferri,V., Costa,F., Accardi,F., Craviotto,L., Aversa,F. and Giuliani,N. The proteasome inhibitor bortezomib maintains osteocyte viability in multiple myeloma patients by reducing both apoptosis and autophagy: a new function for proteasome inhibitors J Bone Miner Res (2016) 31, 815-827. PubMed Europe PubMed DOI I
Wu,Y.X., Yang,J.H. and Saitsu,H. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance Oncotarget (2016) 7, 77622-77634. PubMed Europe PubMed DOI I
Zhang,Y., Cheng,J., Zhang,J., Wu,X., Chen,F., Ren,X., Wang,Y., Li,Q. and Li,Y. Proteasome inhibitor PS-341 limits macrophage necroptosis by promoting cIAPs-mediated inhibition of RIP1 and RIP3 activation Biochem Biophys Res Commun (2016) 477, 761-767. PubMed Europe PubMed DOI I

2015

Amaya,M., Keck,F., Lindquist,M., Voss,K., Scavone,L., Kehn-Hall,K., Roberts,B., Bailey,C., Schmaljohn,C. and Narayanan,A. The ubiquitin proteasome system plays a role in Venezuelan equine encephalitis virus infection PLoS ONE (2015) 10, e0124792- PubMed Europe PubMed DOI PMC EPMC I
Dolloff,N.G. Emerging therapeutic strategies for overcoming proteasome inhibitor resistance Adv Cancer Res (2015) 127, 191-226. PubMed Europe PubMed DOI I
Glynn,S.J., Gaffney,K.J., Sainz,M.A., Louie,S.G. and Petasis,N.A. Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols Org Biomol Chem (2015) 13, 3887-3899. PubMed Europe PubMed DOI I
Huber,E.M., Heinemeyer,W. and Groll,M. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914 Structure (2015) 23, 407-417. PubMed Europe PubMed DOI S I
Moreira,W., Ngan,G.J., Low,J.L., Poulsen,A., Chia,B.C., Ang,M.J., Yap,A., Fulwood,J., Lakshmanan,U., Lim,J., Khoo,A.Y., Flotow,H., Hill,J., Raju,R.M., Rubin,E.J. and Dick,T. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria MBio (2015) 6, e00253-e00215. PubMed Europe PubMed DOI I
Niewerth,D., Jansen,G., Assaraf,Y.G., Zweegman,S., Kaspers,G.J. and Cloos,J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies Drug Resist Updat (2015) 18, 18-35. PubMed Europe PubMed DOI V I
Roelofs,J. Proteasome inhibition by bortezomib: a left hook and a right punch EBioMedicine (2015) 2, 619-620. PubMed Europe PubMed DOI PMC EPMC I
Teicher,B.A. and Tomaszewski,J.E. Proteasome Inhibitors Biochem Pharmacol (2015) 96, 1-9. PubMed Europe PubMed DOI I

2014

Coelho,S.C., Rocha,S., Pereira,M.C., Juzenas,P. and Coelho,M.A. Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles J Biomed Nanotechnol (2014) 10, 717-723. PubMed Europe PubMed DOI I
Dasgupta,S., Castro,L.M., Dulman,R., Yang,C., Schmidt,M., Ferro,E.S. and Fricker,L.D. Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells PLoS ONE (2014) 9, e103604-e103604. PubMed Europe PubMed DOI PMC EPMC I
Dou,Q.P. and Zonder,J.A. Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on Bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system Curr Cancer Drug Targets (2014) 14, 517-536. PubMed Europe PubMed DOI I
Niewerth,D., Kaspers,G.J., Assaraf,Y.G., van Meerloo,J., Kirk,C.J., Anderl,J., Blank,J.L., van de Ven,P.M., Zweegman,S., Jansen,G. and Cloos,J. Interferon-gamma-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines J Hematol Oncol (2014) 7, 7-7. PubMed Europe PubMed DOI I
Stadelmann,B., Aeschbacher,D., Huber,C., Spiliotis,M., Muller,J. and Hemphill,A. Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes PLoS Negl Trop Dis (2014) 8, e3352-e3352. PubMed Europe PubMed DOI I
Wang,Y.Y., Luan,Y., Zhang,X., Lin,M., Zhang,Z.H., Zhu,X.B., Ma,Y. and Wang,Y.B. Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension Clin Exp Med (2014) 14, 321-329. PubMed Europe PubMed DOI I
Yucel,G., Van Arnam,J., Means,P.C., Huntzicker,E., Altindag,B., Lara,M.F., Yuan,J., Kuo,C. and Oro,A.E. Partial proteasome inhibitors induce hair follicle growth by stabilizing beta-catenin Stem Cells (2014) 32, 85-92. PubMed Europe PubMed DOI I

2013

Agyin,J.K., Santhamma,B. and Roy,S.S. Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma Bioorg Med Chem Lett (2013) 23, 6455-6458. PubMed Europe PubMed DOI I
Araujo,K.P., Bonuccelli,G., Duarte,C.N., Gaiad,T.P., Moreira,D.F., Feder,D., Belizario,J.E., Miglino,M.A., Lisanti,M.P. and Ambrosio,C.E. Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs PLoS ONE (2013) 8, e61367-e61367. PubMed Europe PubMed DOI PMC EPMC I
Cao,B., Li,J. and Mao,X. Dissecting bortezomib: development, application, adverse effects and future direction Curr Pharm Des (2013) 19, 3190-3200. PubMed Europe PubMed V I
Chen,F.T., Yang,C.M. and Yang,C.H. The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina PLoS ONE (2013) 8, e64262-e64262. PubMed Europe PubMed DOI PMC EPMC I
Dimopoulos,M.A., Terpos,E. and Kastritis,E. Proteasome inhibitor therapy for Waldenstrom's macroglobulinemia Clin Lymphoma Myeloma Leuk (2013) 13, 235-237. PubMed Europe PubMed DOI I
Escalante,A.M., McGrath,R.T., Karolak,M.R., Dorr,R.T., Lynch,R.M. and Landowski,T.H. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo Cancer Chemother Pharmacol (2013) 71, 1567-1576. PubMed Europe PubMed DOI I
Ito,K., Kobayashi,M., Kuroki,S., Sasaki,Y., Iwata,T., Mori,K., Kuroki,T., Ozawa,Y., Tetsuka,M., Nakagawa,T., Hiroi,T., Yamamoto,H., Ono,K., Washizu,T. and Bonkobara,M. The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo Vet J (2013) 198, 577-582. PubMed Europe PubMed DOI I
Leung-Hagesteijn,C., Erdmann,N., Cheung,G., Keats,J.J., Stewart,A.K., Reece,D.E., Chung,K.C. and Tiedemann,R.E. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma Cancer Cell (2013) 24, 289-304. PubMed Europe PubMed DOI I
Li,A.C., Yu,E., Ring,S.C. and Chovan,J.P. Boronic acid-containing proteasome inhibitors: alert to potential pharmaceutical bioactivation Chem Res Toxicol (2013) 26, 608-615. PubMed Europe PubMed DOI I
Lu,S. and Wang,J. The resistance mechanisms of proteasome inhibitor bortezomib Biomark Res (2013) 1, 13-13. PubMed Europe PubMed DOI I
Matteson,D.S. Boronic esters in asymmetric synthesis J Org Chem (2013) 78, 10009-10023. PubMed Europe PubMed DOI I
Orlowski,R.Z. Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma Cancer Cell (2013) 24, 275-277. PubMed Europe PubMed DOI I
Sridhar,S., Bhat,G. and Guruprasad,K. Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome SpringerPlus (2013) 2, 566-566. PubMed Europe PubMed DOI PMC EPMC I
Velentzas,P.D., Velentzas,A.D., Mpakou,V.E., Antonelou,M.H., Margaritis,L.H., Papassideri,I.S. and Stravopodis,D.J. Detrimental effects of proteasome inhibition activity in Drosophila melanogaster: implication of ER stress, autophagy, and apoptosis Cell Biol Toxicol (2013) 29, 13-37. PubMed Europe PubMed DOI I
Zaouali,M.A., Bardag-Gorce,F., Carbonell,T., Oliva,J., Pantazi,E., Bejaoui,M., Abdennebi,H.B., Rimola,A. and Rosello-Catafau,J. Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury Exp Mol Pathol (2013) 94, 352-359. PubMed Europe PubMed DOI I

2012

Altmann,A., Markert,A., Askoxylakis,V., Schoning,T., Jesenofsky,R., Eisenhut,M. and Haberkorn,U. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma J Nucl Med (2012) 53, 1764-1771. PubMed Europe PubMed DOI I
Berkers,C.R., Leestemaker,Y., Schuurman,K.G., Ruggeri,B., Jones-Bolin,S., Williams,M. and Ovaa,H. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib Mol Pharm (2012) 9, 1126-1135. PubMed Europe PubMed DOI I
Caballero-Velazquez,T., Sanchez-Abarca,L.I., Gutierrez-Cosio,S., Blanco,B., Calderon,C., Herrero,C., Carrancio,S., Serrano,C., Del Canizo,C., San Miguel,J.F. and Perez-Simon,J.A. The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation Haematologica (2012) 97, 1329-1337. PubMed Europe PubMed DOI I
de Wilt,L.H., Jansen,G., Assaraf,Y.G., van Meerloo,J., Cloos,J., Schimmer,A.D., Chan,E.T., Kirk,C.J., Peters,G.J. and Kruyt,F.A. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer Biochem Pharmacol (2012) 83, 207-217. PubMed Europe PubMed DOI I
Eriksson,E., Zaman,F., Chrysis,D., Wehtje,H., Heino,T.J. and Savendahl,L. Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice PLoS ONE (2012) 7, e50523-e50523. PubMed Europe PubMed DOI PMC EPMC I
Esseltine,D.L. and Mulligan,G. An historic perspective of proteasome inhibition Semin Hematol (2012) 49, 196-206. PubMed Europe PubMed DOI V I
Everly,M.J., Terasaki,P.I. and Trivedi,H.L. Durability of antibody removal following proteasome inhibitor-based therapy Transplantation (2012) 93, 572-577. PubMed Europe PubMed DOI I
Fang,H.T., Zhang,B., Pan,X.F., Gao,L., Zhen,T., Zhao,H.X., Ma,L., Xie,J., Liu,Z., Yu,X.J., Cheng,X., Feng,T.T., Zhang,F.X., Yang,Y., Hu,Z.G., Sheng,G.Q., Chen,Y.L., Chen,S.J., Chen,Z. and Zhou,G.B. Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells Proc Natl Acad Sci U S A (2012) 109, 2521-2526. PubMed Europe PubMed DOI I
Franke,N.E., Niewerth,D., Assaraf,Y.G., van Meerloo,J., Vojtekova,K., van Zantwijk,C.H., Zweegman,S., Chan,E.T., Kirk,C.J., Geerke,D.P., Schimmer,A.D., Kaspers,G.J., Jansen,G. and Cloos,J. Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells Leukemia (2012) 26, 757-768. PubMed Europe PubMed DOI M I
Gu,J.L., Li,J., Zhou,Z.H., Liu,J.R., Huang,B.H., Zheng,D. and Su,C. Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma Biochem Biophys Res Commun (2012) 420, 644-650. PubMed Europe PubMed DOI I
Huang,C., Hu,X., Wang,L., Lu,S., Cheng,H., Song,X., Wang,J. and Yang,J. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro Cancer Chemother Pharmacol (2012) 70, 801-809. PubMed Europe PubMed DOI I
Kale,A.J. and Moore,B.S. Molecular mechanisms of acquired proteasome inhibitor resistance J Med Chem (2012) 55, 10317-10327. PubMed Europe PubMed DOI I
Khan,T.M., Benaich,N., Malone,C.F., Bernardos,R.L., Russell,A.R., Downes,G.B., Barresi,M.J. and Hutson,L.D. Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish J Peripher Nerv Syst (2012) 17, 76-89. PubMed Europe PubMed DOI I
Mao,X., Pan,X., Cheng,T. and Zhang,X. Therapeutic potential of the proteasome inhibitor bortezomib on titanium particle-induced inflammation in a murine model Inflammation (2012) 35, 905-912. PubMed Europe PubMed DOI I
Mao,X., Pan,X., Zhao,S., Peng,X., Cheng,T. and Zhang,X. Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo Inflammation (2012) 35, 1378-1391. PubMed Europe PubMed DOI I
Momose,I., Tatsuda,D., Ohba,S., Masuda,T., Ikeda,D. and Nomoto,A. In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter Cancer Sci (2012) 103, 1730-1736. PubMed Europe PubMed DOI L I
Nishihori,T., Alekshun,T.J., Shain,K., Sullivan,D.M., Baz,R., Perez,L., Pidala,J., Kharfan-Dabaja,M.A., Ochoa-Bayona,J.L., Fernandez,H.F., Yarde,D.N., Oliveira,V., Fulp,W., Han,G., Kim,J., Chen,D.T., Raychaudhuri,J., Dalton,W., Anasetti,C. and Alsina,M. Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma Br J Haematol (2012) 157, 553-563. PubMed Europe PubMed DOI I
Padrissa-Altes,S., Zaouali,M.A., Boncompagni,E., Bonaccorsi-Riani,E., Carbonell,T., Bardag-Gorce,F., Oliva,J., French,S.W., Bartrons,R. and Rosello-Catafau,J. The use of a reversible proteasome inhibitor in a model of reduced-size orthotopic liver transplantation in rats Exp Mol Pathol (2012) 93, 99-110. PubMed Europe PubMed DOI I
Paterno,F., Shiller,M., Tillery,G., O'Leary,J.G., Susskind,B., Trotter,J. and Klintmalm,G.B. Bortezomib for acute antibody-mediated rejection in liver transplantation Am J Transplant (2012) 12, 2526-2531. PubMed Europe PubMed DOI I
Sato,A., Asano,T., Ito,K. and Asano,T. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells Urology (2012) 79, 966-921. PubMed Europe PubMed DOI I
Sureshkumar,K.K., Hussain,S.M., Marcus,R.J., Ko,T.Y., Khan,A.S., Tom,K., Vivas,C.A., Parris,G., Jasnosz,K.M. and Thai,N.L. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation Clin Nephrol (2012) 77, 246-253. PubMed Europe PubMed I
Wunderlich,A., Arndt,T., Fischer,M., Roth,S., Ramaswamy,A., Greene,B.H., Brendel,C., Hinterseher,U., Bartsch,D.K. and Hoffmann,S. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer J Surg Oncol (2012) 105, 357-364. PubMed Europe PubMed DOI I
Zeng,Z., Zheng,L., Lin,J. and Chen,J. Successful bortezomib treatment in combination with dexamethasone and thalidomide for previously untreated epidural plasmacytoma Oncol Lett (2012) 3, 557-559. PubMed Europe PubMed DOI PMC EPMC I
Zhang,L., Teng,Y., Zhang,Y., Liu,J., Xu,L., Qu,J., Hou,K., Liu,Y. and Qu,X. Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration Mol Med Rep (2012) 5, 580-584. PubMed Europe PubMed DOI I

2011

Arastu-Kapur,S., Anderl,J.L., Kraus,M., Parlati,F., Shenk,K.D., Lee,S.J., Muchamuel,T., Bennett,M.K., Driessen,C., Ball,A.J. and Kirk,C.J. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events Clin Cancer Res (2011) 17, 2734-2743. PubMed Europe PubMed DOI I
Bardag-Gorce,F. Proteasome inhibitor treatment in alcoholic liver disease World J Gastroenterol (2011) 17, 2558-2562. PubMed Europe PubMed DOI PMC EPMC I
Blanco,B., Sanchez-Abarca,L.I., Caballero-Velazquez,T., Santamaria,C., Inoges,S. and Perez-Simon,J.A. Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens Leuk Res (2011) 35, 1412-1415. PubMed Europe PubMed DOI I
Chen,D., Frezza,M., Schmitt,S., Kanwar,J. and Dou,Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives Curr Cancer Drug Targets (2011) 11, 239-253. PubMed Europe PubMed DOI I
Chen,F., Pisklakova,A., Li,M., Baz,R., Sullivan,D.M. and Nefedova,Y. Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma Cell Oncol (Dordr) (2011) 34, 545-551. PubMed Europe PubMed DOI I
Cvek,B. and Dvorak,Z. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib Curr Pharm Des (2011) 17, 1483-1499. PubMed Europe PubMed DOI I
Escobar,M., Velez,M., Belalcazar,A., Santos,E.S. and Raez,L.E. The role of proteasome inhibition in nonsmall cell lung cancer J Biomed Biotechnol (2011) 2011, 806506-806506. PubMed Europe PubMed DOI PMC EPMC V I
Gryder,B.E., Guerrant,W., Chen,C.H. and Oyelere,A.K. Oxathiazole-2-one derivative of bortezomib: synthesis, stability and proteasome inhibition activity MedChemComm (2011) 2, 1083-1086. DOI I
Liu,J., Zhan,Y.H., Liu,Y.P., Qu,X.J., Xu,L., Zhang,Y., Hou,K.Z. and Hu,X.J. In vitro antitumor effect of the proteasome inhibitor bortezomib on human gastric cancer SGC7901 cells World Chin J Dig (2011) 19, 1441-1445. I
Nakata,W., Hayakawa,Y., Nakagawa,H., Sakamoto,K., Kinoshita,H., Takahashi,R., Hirata,Y., Maeda,S. and Koike,K. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer Int J Oncol (2011) 39, 1529-1536. PubMed Europe PubMed DOI I
Polzer,K., Neubert,K., Meister,S., Frey,B., Baum,W., Distler,J.H., Guckel,E., Schett,G., Voll,R.E. and Zwerina,J. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis Arthritis Rheum (2011) 63, 670-680. PubMed Europe PubMed DOI I
Shahshahan,M.A., Beckley,M.N. and Jazirehi,A.R. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects Am J Cancer Res (2011) 1, 913-924. PubMed Europe PubMed PMC EPMC I
Shaughnessy,J.D., Jr., Qu,P., Usmani,S., Heuck,C.J., Zhang,Q., Zhou,Y., Tian,E., Hanamura,I., van Rhee,F., Anaissie,E., Epstein,J., Nair,B., Stephens,O., Williams,R., Waheed,S., Alsayed,Y., Crowley,J. and Barlogie,B. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3 Blood (2011) 118, 3512-3524. PubMed Europe PubMed DOI I
van Dijk,M., Murphy,E., Morrell,R., Knapper,S., O'Dwyer,M., Samali,A. and Szegezdi,E. The proteasome inhibitor bortezomib sensitizes AML with myelomonocytic differentiation to TRAIL mediated apoptosis Cancers (2011) 3, 1329-1350. PubMed Europe PubMed DOI I
van Hees,H., Ottenheijm,C., Ennen,L., Linkels,M., Dekhuijzen,R. and Heunks,L. Proteasome inhibition improves diaphragm function in an animal model for COPD Am J Physiol Lung Cell Mol Physiol (2011) 301, L110-L116. PubMed Europe PubMed DOI I

2010

Albero,M.P., Vaquer,J.M., Andreu,E.J., Villanueva,J.J., Franch,L., Ivorra,C., Poch,E., Agirre,X., Prosper,F. and Perez-Roger,I. Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells Oncogene (2010) 29, 3276-3286. PubMed Europe PubMed DOI I
Chari,A., Mazumder,A. and Jagannath,S. Proteasome inhibition and its therapeutic potential in multiple myeloma Biologics (2010) 4, 273-287. PubMed Europe PubMed DOI PMC EPMC I
Dudek,S.E., Luig,C., Pauli,E.K., Schubert,U. and Ludwig,S. The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state J Virol (2010) 84, 9439-9451. PubMed Europe PubMed DOI I
Eda,H., Aoki,K., Kato,S., Okawa,Y., Takada,K., Tanaka,T., Marumo,K. and Ohkawa,K. The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells Eur J Haematol (2010) 85, 68-75. PubMed Europe PubMed DOI I
Florea,B.I., Verdoes,M., Li,N., van der Linden,W.A., Geurink,P.P., van den Elst,H., Hofmann,T., de Ru,A., van Veelen,P.A., Tanaka,K., Sasaki,K., Murata,S., den Dulk,H., Brouwer,J., Ossendorp,F.A., Kisselev,A.F. and Overkleeft,H.S. Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t Chem Biol (2010) 17, 795-801. PubMed Europe PubMed DOI PMC EPMC P I
Huan,C. and Zenilman,M.E. A proteasome inhibitor to treat acute pancreatitis? Maybe J Surg Res (2010) 162, 39-41. PubMed Europe PubMed DOI I
Jones,M.D., Liu,J.C., Barthel,T.K., Hussain,S., Lovria,E., Cheng,D., Schoonmaker,J.A., Mulay,S., Ayers,D.C., Bouxsein,M.L., Stein,G.S., Mukherjee,S. and Lian,J.B. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes Clin Cancer Res (2010) 16, 4978-4989. PubMed Europe PubMed DOI I
Li,C., Chen,S., Yue,P., Deng,X., Lonial,S., Khuri,F.R. and Sun,S.Y. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation J Biol Chem (2010) 285, 16096-16104. PubMed Europe PubMed DOI I
Li,T., Ho,L., Piperdi,B., Elrafei,T., Camacho,F.J., Rigas,J.R., Perez-Soler,R. and Gucalp,R. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC) Lung Cancer (2010) 68, 89-93. PubMed Europe PubMed DOI I
Panischeva,L.A., Kakpakova,E.S., Rybalkina,E.Y. and Stavrovskaya,A.A. The influence of proteasome inhibitor Bortezomib on ABC transporters' expression and activity in tumor cells Biol Membrany (2010) 27, 195-201. I
Periyasamy-Thandavan,S., Jackson,W.H., Samaddar,J.S., Erickson,B., Barrett,J.R., Raney,L., Gopal,E., Ganapathy,V., Hill,W.D., Bhalla,K.N. and Schoenlein,P.V. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells Autophagy (2010) 6, 19-35. PubMed Europe PubMed DOI I
Raaben,M., Grinwis,G.C., Rottier,P.J. and de Haan,C.A. The proteasome inhibitor velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice J Virol (2010) 84, 7880-7885. PubMed Europe PubMed DOI I
Schmidt,N., Gonzalez,E., Visekruna,A., Kuhl,A.A., Loddenkemper,C., Mollenkopf,H., Kaufmann,S.H., Steinhoff,U. and Joeris,T. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis Gut (2010) 59, 896-906. PubMed Europe PubMed DOI K I
Seeger,J.M., Schmidt,P., Brinkmann,K., Hombach,A.A., Coutelle,O., Zigrino,P., Wagner-Stippich,D., Mauch,C., Abken,H., Kronke,M. and Kashkar,H. The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack Cancer Res (2010) 70, 1825-1834. PubMed Europe PubMed DOI I
Tilahun,A.Y., Theuer,J.E., Patel,R., David,C.S. and Rajagopalan,G. Detrimental Effect of the Proteasome Inhibitor, Bortezomib in Bacterial Superantigen- and Lipopolysaccharide-induced Systemic Inflammation Mol Ther (2010) 18, 1143-1154. PubMed Europe PubMed DOI I
Walsh,R.C., Everly,J.J., Brailey,P., Rike,A.H., Arend,L.J., Mogilishetty,G., Govil,A., Roy-Chaudhury,P., Alloway,R.R. and Woodle,E.S. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection Transplantation (2010) 89, 277-284. PubMed Europe PubMed DOI I
Wang,Y., Rishi,A.K., Puliyappadamba,V.T., Sharma,S., Yang,H., Tarca,A., Ping Dou,Q., Lonardo,F., Ruckdeschel,J.C., Pass,H.I. and Wali,A. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines Cancer Chemother Pharmacol (2010) 66, 455-466. PubMed Europe PubMed DOI I
Yannaki,E., Papadopoulou,A., Athanasiou,E., Kaloyannidis,P., Paraskeva,A., Bougiouklis,D., Palladas,P., Yiangou,M. and Anagnostopoulos,A. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats Arthritis Rheum (2010) 62, 3277-3288. PubMed Europe PubMed DOI I

2009

Basler,M., Lauer,C., Beck,U. and Groettrup,M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection J Immunol (2009) 183, 6145-6150. PubMed Europe PubMed DOI I
Everly,J.J., Walsh,R.C., Alloway,R.R. and Woodle,E.S. Proteasome inhibition for antibody-mediated rejection Curr Opin Organ Transplant (2009) 14, 662-666. PubMed Europe PubMed DOI I
Heider,U., Rademacher,J., Lamottke,B., Mieth,M., Moebs,M., von Metzler,I., Assaf,C. and Sezer,O. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma Eur J Haematol (2009) 82, 440-449. PubMed Europe PubMed DOI I
Huber,J.M., Tagwerker,A., Heininger,D., Mayer,G., Rosenkranz,A.R. and Eller,K. The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury Am J Physiol Renal Physiol (2009) 297, F451-F460. PubMed Europe PubMed DOI I
Kubicek,G.J., Werner-Wasik,M., Machtay,M., Mallon,G., Myers,T., Ramirez,M., Andrews,D., Curran,W.J., Jr. and Dicker,A.P. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies Int J Radiat Oncol Biol Phys (2009) 74, 433-439. PubMed Europe PubMed DOI PMC EPMC I
Lee,S.W., Kim,J.H., Park,Y.B. and Lee,S.K. Bortezomib attenuates murine collagen-induced arthritis Ann Rheum Dis (2009) 68, 1761-1767. PubMed Europe PubMed DOI I
Ruckrich,T., Kraus,M., Gogel,J., Beck,A., Ovaa,H., Verdoes,M., Overkleeft,H.S., Kalbacher,H. and Driessen,C. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells Leukemia (2009) 23, 1098-1105. PubMed Europe PubMed DOI I
Shah,J.J. and Orlowski,R.Z. Proteasome inhibitors in the treatment of multiple myeloma Leukemia (2009) 23, 1964-1979. PubMed Europe PubMed DOI I
Steverding,D. and Wang,X. Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib Parasit Vectors (2009) 2, 29-29. PubMed Europe PubMed DOI PMC EPMC I
Testa,U. Proteasome inhibitors in cancer therapy Curr Drug Targets (2009) 10, 968-981. PubMed Europe PubMed DOI I
Vaziri,S.A., Grabowski,D.R., Hill,J., Rybicki,L.R., Burk,R., Bukowski,R.M., Ganapathi,M.K. and Ganapathi,R. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent Anticancer Res (2009) 29, 2961-2969. PubMed Europe PubMed I

2008

Colado,E., Alvarez-Fernandez,S., Maiso,P., Martin-Sanchez,J., Vidriales,M.B., Garayoa,M., Ocio,E.M., Montero,J.C., Pandiella,A. and San Miguel,J.F. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype Haematologica (2008) 93, 57-66. PubMed Europe PubMed DOI I
Davies,A.M., Ruel,C., Lara,P.N., Lau,D.H., Gumerlock,P.H., Bold,R., Shibata,S., Lenz,H.J., Schenkein,D.P. and Gandara,D.R. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study J Thorac Oncol (2008) 3, 68-74. PubMed Europe PubMed DOI I
Fuchs,D., Berges,C., Opelz,G., Daniel,V. and Naujokat,C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells J Cell Biochem (2008) 103, 270-283. PubMed Europe PubMed DOI I
Lu,G., Punj,V. and Chaudhary,P.M. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL Cancer Biol Ther (2008) 7, 603-608. PubMed Europe PubMed I
Lu,S., Yang,J., Song,X., Gong,S., Zhou,H., Guo,L., Song,N., Bao,X., Chen,P. and Wang,J. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of jurkat T cell lymphoblastic lymphoma/leukemia line J Pharmacol Exp Ther (2008) 326, 423-431. PubMed Europe PubMed DOI M I
Meiners,S., Ludwig,A., Stangl,V. and Stangl,K. Proteasome inhibitors: poisons and remedies Med Res Rev (2008) 28, 309-327. PubMed Europe PubMed DOI I
Moore,B.S., Eustaquio,A.S. and McGlinchey,R.P. Advances in and applications of proteasome inhibitors Curr Opin Chem Biol (2008) 12, 434-440. PubMed Europe PubMed DOI PMC EPMC I
Nawrocki,S.T., Carew,J.S., Maclean,K.H., Courage,J.F., Huang,P., Houghton,J.A., Cleveland,J.L., Giles,F.J. and McConkey,D.J. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA Blood (2008) 112, 2917-2926. PubMed Europe PubMed DOI PMC EPMC I
Oerlemans,R., Franke,N.E., Assaraf,Y.G., Cloos,J., van Zantwijk,I., Berkers,C.R., Scheffer,G.L., Debipersad,K., Vojtekova,K., Lemos,C., van der Heijden,J.W., Ylstra,B., Peters,G.J., Kaspers,G.L., Dijkmans,B.A., Scheper,R.J. and Jansen,G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood (2008) 112, 2489-2499. PubMed Europe PubMed DOI M I

2007

Bonuccelli,G., Sotgia,F., Capozza,F., Gazzerro,E., Minetti,C. and Lisanti,M.P. Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice Cell Cycle (2007) 6, 1242-1248. PubMed Europe PubMed I
Fujita,T., Doihara,H., Washio,K., Ino,H., Murakami,M., Naito,M. and Shimizu,N. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells Anticancer Drugs (2007) 18, 677-686. PubMed Europe PubMed DOI I
Kanagasabaphy,P., Morgan,G.J. and Davies,F.E. Proteasome inhibition and multiple myeloma Curr Opin Investig Drugs (2007) 8, 447-451. PubMed Europe PubMed I
Kimura,F. Proteasome inhibitor, bortezomib Biotherapy (Japan) (2007) 21, 247-255. I
Kraus,M., Ruckrich,T., Reich,M., Gogel,J., Beck,A., Kammer,W., Berkers,C.R., Burg,D., Overkleeft,H., Ovaa,H. and Driessen,C. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells Leukemia (2007) 21, 84-92. PubMed Europe PubMed DOI I
Li,Y., Plesescu,M., Sheehan,P., Daniels,J.S. and Prakash,S.R. Synthesis of four isotopically labeled forms of a proteasome inhibitor, bortezomib J Labelled Comp Radiopharm (2007) 50, 402-406. DOI I
Mattingly,L.H., Gault,R.A. and Murphy,W.J. Use of systemic proteasome inhibition as an immune-modulating agent in disease Endocr Metab Immune Disord Drug Targets (2007) 7, 29-34. PubMed Europe PubMed I
Mulligan,G., Mitsiades,C., Bryant,B., Zhan,F., Chng,W.J., Roels,S., Koenig,E., Fergus,A., Huang,Y., Richardson,P., Trepicchio,W.L., Broyl,A., Sonneveld,P., Shaughnessy,J.D., Jr., Bergsagel,P.L., Schenkein,D., Esseltine,D.L., Boral,A. and Anderson,K.C. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib Blood (2007) 109, 3177-3188. PubMed Europe PubMed DOI I
Oyajobi,B.O., Garrett,I.R., Gupta,A., Flores,A., Esparza,J., Munoz,S., Zhao,M. and Mundy,G.R. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease Br J Haematol (2007) 139, 434-438. PubMed Europe PubMed DOI I
Poulaki,V., Mitsiades,C.S., Kotoula,V., Negri,J., McMillin,D., Miller,J.W. and Mitsiades,N. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro Invest Ophthalmol Vis Sci (2007) 48, 4706-4719. PubMed Europe PubMed DOI I
Reynolds,J.M., El Bissati,K., Brandenburg,J., Gunzl,A. and Mamoun,C.B. Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B BMC Clin Pharmacol (2007) 7, 13-13. PubMed Europe PubMed DOI PMC EPMC I
Tobinai,K. Proteasome inhibitor, bortezomib, for myeloma and lymphoma Int J Clin Oncol (2007) 12, 318-326. PubMed Europe PubMed DOI I
Zavrski,I., Kleeberg,L., Kaiser,M., Fleissner,C., Heider,U., Sterz,J., Jakob,C. and Sezer,O. Proteasome as an emerging therapeutic target in cancer Curr Pharm Des (2007) 13, 471-485. PubMed Europe PubMed DOI I
Zinzani,P.L., Musuraca,G., Tani,M., Stefoni,V., Marchi,E., Fina,M., Pellegrini,C., Alinari,L., Derenzini,E., de Vivo,A., Sabattini,E., Pileri,S. and Baccarani,M. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma J Clin Oncol (2007) 25, 4293-4297. PubMed Europe PubMed DOI I

2006

[YEAR:22-6-2006]Anan,A., Baskin-Bey,E.S., Isomoto,H., Mott,J.L., Bronk,S.F., Albrecht,J.H. and Gores,G.J. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse Am J Physiol Gastrointest Liver Physiol (22-6-2006) 291, G709-G716. PubMed Europe PubMed DOI I
[YEAR:7-8-2006]Bai,J., Demirjian,A., Sui,J., Marasco,W. and Callery,M.P. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells Biochem Biophys Res Commun (7-8-2006) 348, 1245-1253. PubMed Europe PubMed DOI I
[YEAR:29-6-2006]Cavo,M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma Leukemia (29-6-2006) 20, 1341-1352. PubMed Europe PubMed DOI I
Codony-Servat,J., Tapia,M.A., Bosch,M., Oliva,C., Domingo-Domenech,J., Mellado,B., Rolfe,M., Ross,J.S., Gascon,P., Rovira,A. and Albanell,J. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells Mol Cancer Ther (2006) 5, 665-675. PubMed Europe PubMed DOI I
[YEAR:23-8-2006]Fribley,A.M., Evenchik,B., Zeng,Q., Park,B.K., Guan,J.Y., Zhang,H., Hale,T.J., Soengas,M.S., Kaufman,R.J. and Wang,C.Y. Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa J Biol Chem (23-8-2006) 281, 31440-31447. PubMed Europe PubMed DOI I
Fujita,T., Doihara,H., Washio,K., Kawasaki,K., Takabatake,D., Takahashi,H., Tsukuda,K., Ogasawara,Y. and Shimizu,N. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells Anticancer Drugs (2006) 17, 455-462. PubMed Europe PubMed DOI I
[YEAR:19-1-2006]Goel,A., Dispenzieri,A., Geyer,S.M., Greiner,S., Peng,K.W. and Russell,S.J. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma Blood (19-1-2006) 107, 4063-4070. PubMed Europe PubMed DOI PMC EPMC I
Groll,M., Berkers,C.R., Ploegh,H.L. and Ovaa,H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome Structure (2006) 14, 451-456. PubMed Europe PubMed DOI S I
[YEAR:18-2-2006]Henninger,N., Sicard,K.M., Bouley,J., Fisher,M. and Stagliano,N.E. The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia Neurosci Lett (18-2-2006) 398, 300-305. PubMed Europe PubMed DOI I
Labutti,J., Parsons,I., Huang,R., Miwa,G., Gan,L.S. and Daniels,J.S. Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome p450 reaction Chem Res Toxicol (2006) 19, 539-546. PubMed Europe PubMed DOI I
Mitsiades,C.S., Mitsiades,N., Hideshima,T., Richardson,P.G. and Anderson,K.C. Proteasome inhibition as a new therapeutic principle in hematological malignancies Curr Drug Targets (2006) 7, 1341-1347. PubMed Europe PubMed DOI I
[YEAR:14-3-2006]Nencioni,A., Schwarzenberg,K., Brauer,K.M., Schmidt,S.M., Ballestrero,A., Grunebach,F. and Brossart,P. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation Blood (14-3-2006) 108, 551-558. PubMed Europe PubMed DOI I
Orlowski,R.Z. and Zeger,E.L. Targeting the proteasome as a therapeutic strategy against haematological malignancies Expert Opin Investig Drugs (2006) 15, 117-130. PubMed Europe PubMed DOI I
Richardson,P.G., Mitsiades,C., Hideshima,T. and Anderson,K.C. Bortezomib: proteasome inhibition as an effective anticancer therapy Annu Rev Med (2006) 57, 33-47. PubMed Europe PubMed DOI I
Richardson,P.G., Barlogie,B., Berenson,J., Singhal,S., Jagannath,S., Irwin,D.H., Rajkumar,S.V., Srkalovic,G., Alsina,M. and Anderson,K.C. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial Cancer (2006) 106, 1316-1319. PubMed Europe PubMed DOI I
[YEAR:15-4-2006]Schumacher,L.Y., Vo,D.D., Garban,H.J., Comin-Anduix,B., Owens,S.K., Dissette,V.B., Glaspy,J.A., McBride,W.H., Bonavida,B., Economou,J.S. and Ribas,A. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade) J Immunol (15-4-2006) 176, 4757-4765. PubMed Europe PubMed I
Stubblefield,M.D., Slovin,S., MacGregor-Cortelli,B., Muzzy,J., Scher,H., Wright,J., Esseltine,D., Schenkein,D. and O'Connor,O.A. An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib Clin Oncol (R Coll Radiol) (2006) 18, 410-418. PubMed Europe PubMed DOI I
[YEAR:1-1-2006]Zou,W., Yue,P., Lin,N., He,M., Zhou,Z., Lonial,S., Khuri,F.R., Wang,B. and Sun,S.Y. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells Clin Cancer Res (1-1-2006) 12, 273-280. PubMed Europe PubMed DOI I

2005

Berkers,C.R., Verdoes,M., Lichtman,E., Fiebiger,E., Kessler,B.M., Anderson,K.C., Ploegh,H.L., Ovaa,H. and Galardy,P.J. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib Nat Methods (2005) 2, 357-362. PubMed Europe PubMed DOI I
Jackson,G., Einsele,H., Moreau,P. and Miguel,J.S. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies Cancer Treat Rev (2005) 31, 591-602. PubMed Europe PubMed DOI V I
[YEAR:21-9-2005]Ludwig,H., Khayat,D., Giaccone,G. and Facon,T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies Cancer (21-9-2005) 104, 1794-1807. PubMed Europe PubMed DOI I
Mitsiades,C.S., Mitsiades,N., Hideshima,T., Richardson,P.G. and Anderson,K.C. Proteasome inhibition as a therapeutic strategy for hematologic malignancies Expert Rev Anticancer Ther (2005) 5, 465-476. PubMed Europe PubMed DOI I
[YEAR:20-1-2005]Rajkumar,S.V., Richardson,P.G., Hideshima,T. and Anderson,K.C. Proteasome inhibition as a novel therapeutic target in human cancer J Clin Oncol (20-1-2005) 23, 630-639. PubMed Europe PubMed DOI V I
Richardson,P.G. and Mitsiades,C. Bortezomib: proteasome inhibition as an effective anticancer therapy Future Oncol (2005) 1, 161-171. PubMed Europe PubMed DOI I

2004

Adams,J. and Kauffman,M. Development of the proteasome inhibitor Velcade (Bortezomib) Cancer Invest (2004) 22, 304-311. PubMed Europe PubMed DOI I
[YEAR:1-1-2004]Davis,N.B., Taber,D.A., Ansari,R.H., Ryan,C.W., George,C., Vokes,E.E., Vogelzang,N.J. and Stadler,W.M. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study J Clin Oncol (1-1-2004) 22, 115-119. PubMed Europe PubMed DOI I

2003

Giuliano,M., D'Anneo,A., De Blasio,A., Vento,R. and Tesoriere,G. Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs Ital J Biochem (2003) 52, 112-121. PubMed Europe PubMed I

2002

Adams,J. The proteasome as a novel target for the treatment of breast cancer Breast Dis (2002) 15, 61-70. PubMed Europe PubMed T I

2000

Rivett,A.J. and Gardner,R.C. Proteasome inhibitors: from in vitro uses to clinical trials J Pept Sci (2000) 6, 478-488. PubMed Europe PubMed DOI V I

1999

[YEAR:1-6-1999]Adams,J., Palombella,V.J., Sausville,E.A., Johnson,J., Destree,A., Lazarus,D.D., Maas,J., Pien,C.S., Prakash,S. and Elliott,P.J. Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res (1-6-1999) 59, 2615-2622. PubMed Europe PubMed I

1998

[YEAR:17-2-1998]Adams,J., Behnke,M., Chen,S., Cruickshank,A.A., Dick,L.R., Grenier,L., Klunder,J.M., Ma,Y.T., Plamondon,L. and Stein,R.L. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids Bioorg Med Chem Lett (17-2-1998) 8, 333-338. PubMed Europe PubMed DOI I
[YEAR:22-12-1998]Palombella,V.J., Conner,E.M., Fuseler,J.W., Destree,A., Davis,J.M., Laroux,F.S., Wolf,R.E., Huang,J., Brand,S., Elliott,P.J., Lazarus,D., McCormack,T., Parent,L., Stein,R., Adams,J. and Grisham,M.B. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis Proc Natl Acad Sci U S A (22-12-1998) 95, 15671-15676. PubMed Europe PubMed DOI PMC EPMC I